ARC grant for Starpharma's targeted drug delivery
Starpharma today announced it had been successful in securing a $548,000 ARC Linkage grant in partnership with Monash University, to further advance the Company’s dendrimer technology in targeted drug delivery including antibody-drug conjugates (ADCs).
The Australian: Starpharma featured in GE Capital Gains Series
Starpharma CEO Dr Jackie Fairley was interviewed for the GE Capital Gains Series by The Australian's Economics Correspondent Adam Creighton.
Starpharma presenting at Nomura Asian Equity Forum
Starpharma will be participating in the Nomura Asia Equity Forum in Singapore. The forum, held June 10–12, has attracted more than 1,500 delegates including management from 133 companies and more than 1,000 investors.
Shareholder Update: May 2013
In this issue:
› VivaGel® update
› New agrochemical partnership
› SPL7013 shows therapeutic potential in viral conjunctivitis
› Positive dendrimer-doxorubicin results
› Key patents obtained
› R&D tax refund received
› Momentum builds in nanomedicine
› Substantial holders increase their stake
Download: Shareholder Update: May 2013 ( pdf file, 1MB)
Starpharma Boardroom Radio Interview
Starpharma is pleased to provide investors with the opportunity to listen to an audio interview with Chief Executive Officer Dr Jackie Fairley on Boardroom Radio (BRR).
Starpharma presenting at Goldman Sachs Emerging Companies Conference
Starpharma will today present to institutional fund managers at the Goldman Sachs Emerging Companies conference in Sydney.
The invitation-only event involves 35 companies across all sectors. Starpharma is one of three healthcare companies invited to attend - the other two are Blackmores and Sigma Pharmaceuticals.
Starpharma's dendrimer a potential viral conjunctivitis treatment
Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) today announced that the Company’s clinical-stage dendrimer SPL7013 has shown potent antiviral effect against adenovirus, the agent responsible for the majority of viral conjunctivitis cases.
Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C - Quarterly Cashflow Report for the period ended 31 March 2013.
Starpharma Granted New Drug Delivery Patents
Starpharma today announced it has been granted three new patents by the United States Patent and Trademark Office (USPTO) which strengthen and expand the Company’s patent estate for its drug delivery platform.
In addition, China’s patent office has also informed the Company that it has allowed a similarly broad, drug delivery-related patent.
The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley
ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Thursday 4th April 2013. Ticky discussed the positive results of Starpharma’s Phase 2 prevention of recurrence BV trials.